$ZVRA News

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports

Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $35

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $29

BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Raises Price Target to $29

Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $25

Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Raises Price Target to $34

Zevra Therapeutics Submits U.S. Patent For MIPLYFFA To FDA For Listing In Orange Book Publication; Patent Expires On November 19, 2041

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25

Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?

Zevra Therapeutics Q1 Earnings Call Highlights

Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary

Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript

Zevra (ZVRA) Q1 2026 Earnings Call Transcript

Zevra Therapeutics (NASDAQ:ZVRA) Shares Surge After Blowout Q1 Earnings Beat